Sionna Therapeutics (NASDAQ:SION) Shares Gap Down – Here’s Why

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price gapped down before the market opened on Monday . The stock had previously closed at $42.38, but opened at $40.91. Sionna Therapeutics shares last traded at $41.41, with a volume of 14,264 shares changing hands.

Wall Street Analysts Forecast Growth

SION has been the topic of a number of research analyst reports. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research report on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. BTIG Research reaffirmed a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a report on Wednesday, January 14th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Stock Up 0.5%

The company has a market cap of $1.90 billion and a P/E ratio of -8.75. The firm’s 50 day moving average is $41.20 and its two-hundred day moving average is $31.56.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Peter A. Thompson sold 33,356 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the transaction, the director owned 3,561,655 shares in the company, valued at $158,671,730.25. This trade represents a 0.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 515,885 shares of company stock worth $21,946,015 over the last quarter. 3.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Braidwell LP bought a new position in Sionna Therapeutics during the second quarter worth $18,770,000. Prudential Financial Inc. raised its holdings in shares of Sionna Therapeutics by 114.6% during the second quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock valued at $2,345,000 after purchasing an additional 72,185 shares during the period. Bosun Asset Management LLC acquired a new position in shares of Sionna Therapeutics during the second quarter valued at about $295,000. JPMorgan Chase & Co. boosted its position in shares of Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after purchasing an additional 51,589 shares in the last quarter. Finally, Aberdeen Group plc grew its stake in shares of Sionna Therapeutics by 27.4% in the 2nd quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock valued at $16,492,000 after buying an additional 204,583 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.